Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Russell-Jones

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Diabetologia|January 31, 2025
Comparison of continuous glucose monitoring with self-monitoring of blood glucose in type 1 diabetes in the changing atmospheric pressures in aviation: a hypobaric flight simulationKa Siu Fan, Antonios Manoli, Petra M Baumann, et al.
Lancet (London, England)|February 24, 2015
Ovarian hyperstimulation from ectopic hypersecretion of follicle stimulating hormoneAlexander D Miras, Julianne T Mogford, John Wright, et al.
Diabetes, Obesity & Metabolism|May 25, 2019
Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trialMelanie J Davies, David Russell-Jones, Thomas M Barber, et al.
Diabetes, Obesity & Metabolism|March 10, 2019
Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetesDavid Russell-Jones, Arnaud Dauchy, Elías Delgado, et al.
Lancet (London, England)|April 24, 2012
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trialSimon Heller, John Buse, Miles Fisher, et al.
Metabolism: Clinical and Experimental|March 27, 2012
Fatty acid flux and oxidation are increased by rimonabant in obese womenKatharine Backhouse, Ivana Sarac, Fariba Shojaee-Moradie, et al.
Plos One|October 20, 2022
Intrapulmonary shunting is a key contributor to hypoxia in COVID-19: An update on the pathophysiologyNikhil Mayor, Harry Knights, Aleksandra Kotwica, et al.
Physiological Reports|April 4, 2018
Fecal Enterobacteriales enrichment is associated with increased in vivo intestinal permeability in humansCamilla Pedersen, Umer Z Ijaz, Edith Gallagher, et al.
Diabetes Care|March 31, 2017
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)David Russell-Jones, Bruce W Bode, Christophe De Block, et al.
The Journal of Clinical Endocrinology and Metabolism|May 8, 2002
Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithmsAnne Kehely, Peter C Bates, Paul Frewer, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Diabetologia|January 31, 2025
Comparison of continuous glucose monitoring with self-monitoring of blood glucose in type 1 diabetes in the changing atmospheric pressures in aviation: a hypobaric flight simulationKa Siu Fan, Antonios Manoli, Petra M Baumann, et al.
Lancet (London, England)|February 24, 2015
Ovarian hyperstimulation from ectopic hypersecretion of follicle stimulating hormoneAlexander D Miras, Julianne T Mogford, John Wright, et al.
Diabetes, Obesity & Metabolism|May 25, 2019
Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trialMelanie J Davies, David Russell-Jones, Thomas M Barber, et al.
Diabetes, Obesity & Metabolism|March 10, 2019
Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetesDavid Russell-Jones, Arnaud Dauchy, Elías Delgado, et al.
Lancet (London, England)|April 24, 2012
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trialSimon Heller, John Buse, Miles Fisher, et al.
Metabolism: Clinical and Experimental|March 27, 2012
Fatty acid flux and oxidation are increased by rimonabant in obese womenKatharine Backhouse, Ivana Sarac, Fariba Shojaee-Moradie, et al.
Plos One|October 20, 2022
Intrapulmonary shunting is a key contributor to hypoxia in COVID-19: An update on the pathophysiologyNikhil Mayor, Harry Knights, Aleksandra Kotwica, et al.
Physiological Reports|April 4, 2018
Fecal Enterobacteriales enrichment is associated with increased in vivo intestinal permeability in humansCamilla Pedersen, Umer Z Ijaz, Edith Gallagher, et al.
Diabetes Care|March 31, 2017
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)David Russell-Jones, Bruce W Bode, Christophe De Block, et al.
The Journal of Clinical Endocrinology and Metabolism|May 8, 2002
Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithmsAnne Kehely, Peter C Bates, Paul Frewer, et al.
Pageof 6